Embarking on a journey through the annals of financial analysis, ETF Channel invites us to scrutinize the zenith that the Vanguard ESG U.S. Stock ETF (ESGV) might scale. The oracle of market prognostication whispers that the ETF’s underlying holdings hint at a forthcoming ascent, with a lofty implied analyst target price of $99.89 per unit.
While ESGV meanders near $91.12 per unit in recent times, the augurs of Wall Street perceive a beckoning 9.63% surge awaiting this ETF when gazing at the average analyst targets for its portfolio constituents. Among them, Arcus Biosciences Inc (RCUS), Akero Therapeutics Inc (AKRO), and Vaxcyte Inc (PCVX) stand out as paragons of potential, flaunting substantial headroom to their respective target prices. RCUS, currently trading at $16.73 per share, boasts an exalted analyst target at $41.62 per share – a towering 148.80% above its present valuation. Likewise, AKRO flaunts a projected 124.32% climb to $49.12 per share, and PCVX is envisioned to elevate to $100.14 per share – a majestic 60.12% north of its current $62.54 valuation. Behold below, a bygone year’s performance waltz of RCUS, AKRO, and PCVX upon the stock charts.
Eager minds may peruse the table below, encapsulating the dream-like analyst target prices:
| Name | Symbol | Recent Price | Avg. Analyst 12-Mo. Target | % Upside to Target |
|---|---|---|---|---|
| Vanguard ESG U.S. Stock ETF | ESGV | $91.12 | $99.89 | 9.63% |
| Arcus Biosciences Inc | RCUS | $16.73 | $41.62 | 148.80% |
| Akero Therapeutics Inc | AKRO | $21.90 | $49.12 | 124.32% |
| Vaxcyte Inc | PCVX | $62.54 | $100.14 | 60.12% |
Do the sages of the Street divine truth, or do they moon about unrealistically on the future of these equities a year hence? Are these price edicts founded on solid bedrock or are they but shadows, cast by the dying embers of a bygone era? A stratospheric target relative to a stock’s current valuation can signify optimism for the morrow, yet can also herald a downfall if those forecasts are but ghosts of yesteryears. These quandaries beckon discerning investors to delve deeper.
10 ETFs With Most Upside To Analyst Targets »
Also see:
– When Mortgage REITs and Hedge Funds Collide.
– A Trip Down TMKR’s Share Count Memory Lane.
– REED’s Average Annual Return: A Stroll Through Yesteryears.
The opinions swirling herein belong to the author alone and do not necessarily mirror those of Nasdaq, Inc.
5 Stocks Our Experts Predict Could Double In the Next Year
By submitting your email, you'll also get a free pivot & flow membership. A free daily market overview. You can unsubscribe at any time.
